CDK6-IN-1, with the CAS number 2743517-28-2, is a selective inhibitor of cyclin-dependent kinase 6 (CDK6), an enzyme that plays a crucial role in cell cycle regulation and is implicated in various cancers. This compound is characterized by its ability to interfere with the phosphorylation of target proteins, thereby inhibiting cell proliferation in cancerous cells that rely on CDK6 for progression through the cell cycle. CDK6-IN-1 exhibits a high degree of selectivity for CDK6 over other kinases, which is essential for minimizing off-target effects and enhancing therapeutic efficacy. The compound is typically evaluated in preclinical studies for its potential in treating hematological malignancies and solid tumors. Its pharmacological profile includes considerations of solubility, stability, and bioavailability, which are critical for its development as a therapeutic agent. As research progresses, CDK6-IN-1 may contribute to targeted cancer therapies, particularly in combination with other treatments to improve patient outcomes.

CDK6-IN-1

2743517-28-2: CDK6-IN-1, with the CAS number 2743517-28-2, is a selective inhibitor of cyclin-dependent kinase 6 (CDK6), an enzyme that plays a crucial role in cell cycle regulation and is implicated in various cancers. This compound is characterized by its ability to interfere with the phosphorylation of target proteins, thereby inhibiting cell proliferation in cancerous cells that rely on CDK6 for progression through the cell cycle. CDK6-IN-1 exhibits a high degree of selectivity for CDK6 over other kinases, which is essential for minimizing off-target effects and enhancing therapeutic efficacy. The compound is typically evaluated in preclinical studies for its potential in treating hematological malignancies and solid tumors. Its pharmacological profile includes considerations of solubility, stability, and bioavailability, which are critical for its development as a therapeutic agent. As research progresses, CDK6-IN-1 may contribute to targeted cancer therapies, particularly in combination with other treatments to improve patient outcomes.

CDK6-IN-1 (compound 4i) is an inhibitor of CDK6 that suppresses cell growth and induces cell cycle arrest at the G1 phase.

CAS 2743517-28-2

CDK6-IN-1

CDK6-IN-1

Ref: TM-T201591